Climate

Developing nations demand trillions in climate finance at COP29

HQ team November 14, 2024: The 29th Conference of the Parties (COP29) to the United Nations Framework Convention on Climate Change (UNFCCC), held.

Read More
Drugs Health Pharma

Global diabetic population rose fourfold to 828 million in 2022

The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India,.

Read More
Health

Researchers develop innovative non-addictive painkiller for chronic pain

HQ Team November 13, 2024: A team of international researchers has developed a non-addictive painkiller that remains inactive until it reaches sites of.

Read More
Climate

Multilateral development banks pledge $120b to climate finance

HQ Team November 13, 2024: At COP29 in Baku, Azerbaijan, multilateral development banks (MBDs) announced a commitment to $120 billion in climate financing.

Read More
Pharma

Danish Pharma ALK pays ARS $145m for Neffy nasal spray licensing deal

HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.

Read More
Climate Health Medical

Tax fossil fuel extraction, aviation, shipping: UN chief says at COP29

UN Secretary-General António Guterres outlined a three-point plan to limit global temperature rise to 1.5 degrees Celsius by 2030, including new ways to.

Read More
Health Medical Opinion

Opinion: Take life head-on; forced positivity is fake confidence

Toxic positivity promotes the belief that individuals should maintain happiness regardless of their circumstances. It discourages negative thoughts, even in situations that naturally.

Read More
Drugs Health Pharma

US drug regulator removes clinical hold on Novavax’s vaccines

Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US.

Read More
Drugs Health Pharma

AstraZeneca to invest $3.5 billion in the US to expand global footprint

Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.

Read More
Drugs Health Pharma

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

Read More